Abstract:The purpose of the use of this methodology is 1) to advance our capacity to protect individuals with antibody or vaccine for preventing or treating histoplasmosis caused by the fungus Histoplasma capsulatum and 2) to examine the role of virulence factors as target for therapy. To generate mAbs, mice are immunized, the immune responses are assessed using a solid phase ELISA system developed in our laboratory, and the best responder mice are selected for isolation of splenocytes for fusion with hybridoma cells. C57BL/6 mice have been extensively used to study H. capsulatum pathogenesis and provide the best model for obtaining the data required. In order to assess the role of the mAbs in infection, mice are intraperitoneally administered with either mAb to H. capsulatum or isotype matched control mAb and then infected by either intravenous (i.v.), intraperitoneal (i.p.), or intranasal (i.n.) routes. In the scientific literature, efficacy of mAbs for fungal infections in mice relies on mortality as an end point, in conjunction with colony forming units (CFU) assessments at earlier time points. Survival (time to death) studies are necessary as they best represent human disease. Thus, efficacy of our intervention would not adequately be established without survival curves. This is also true for establishing efficacy of vaccine or testing of mutants for virulence. With histoplasmosis, the mice often go from being energetic to dead over several hours. The capacity of an intervention such as the administration of a mAb may initially protect an animal from disease, but the disease can relapse which would not be realized in short CFU experiments. In addition to survival and fungal burden assays, we examine the inflammatory responses to infection (histology, cellular recruitment, cytokine responses). For survival/time to death experiments, the mice are infected and monitored at least twice daily for signs of morbidity. To assess fungal burden, histopathology, and cytokine responses, the mice are euthanized at various times after infection. Animal experiments are performed according to the guidelines of the Institute for Animal Studies of the Albert Einstein College of Medicine.

Protection of Hamsters from Amebic Liver Abscess Formation by a Monoclonal Antibody to a 150-Kda Surface Lectin of Entamoeba Histolytica

A monoclonal antibody against the 150-kDa surface antigen of Entamoeba histolytica inhibits adherence and cytotoxicity to mammalian cells

Characterization of Entamoeba Histolytica Intermediate Subunit Lectin-Specific Human Monoclonal Antibodies Generated in Transgenic Mice Expressing Human Immunoglobulin Loci

Evaluation of the C-Terminal Fragment of Entamoeba Histolytica Gal/GalNAc Lectin Intermediate Subunit As a Vaccine Candidate Against Amebic Liver Abscess.

Differentiation of Entamoeba Histolytica from E. Dispar Facilitated by Monoclonal Antibodies Against a 150-Kda Surface Antigen

Characteristics of Inflammatory Reactions During Development of Liver Abscess in Hamsters Inoculated with Entamoeba Nuttalli

Evaluation of the PE Δ III-LC3-KDEL3 Chimeric Protein of Entamoeba histolytica- Lectin as a Vaccine Candidate against Amebic Liver Abscess

Evaluation of novel fusion proteins derived from extracellular matrix binding domains of LigB as vaccine candidates against leptospirosis in a hamster model

Efficacy of the Rabbit Polyclonal Anti-leptospira Antibody against Homotype or Heterotype Leptospira Infection in Hamster

[Studies on Protective Monoclonal Antibodies to Leishmania Donovani].

Passive administration of monoclonal antibodies against H. capsulatum and other fungal pathogens

Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium Difficile Disease in Hamsters

Fate of Entamoeba histolytica during establishment of amoebic liver abscess analyzed by quantitative radioimaging and histology

Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines

[Preparation and Identification of Monoclonal Antibody Against Alpha-Momorcharins].

Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis

Preparation and Characterization of Monoclonal Antibody Against Human LSECtin

VH3 Gene Usage in Neutralizing Human Antibodies Specific for Theentamoeba Histolyticagal/galnac Lectin Heavy Subunit

Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaques

Acquired Hookworm Immunity in the Golden Hamster (mesocricetus Auratus) Elicited by Living Necator Americanus Third-Stage Infective Larvae

Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model